Determination of Carboplatin's Optimal Plasmatic Exposure
NCT ID: NCT00145028
Last Updated: 2009-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
400 participants
INTERVENTIONAL
2005-05-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00812864
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
NCT01261299
Trientine and Carboplatin in Advanced Malignancies
NCT01178112
L-Carnitine Protective Effect in Nephrotoxicity
NCT07108777
A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.
NCT01286831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Neutrophils \> 1500/mm3, blood-platelets \> 100000/mm3
* Patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for Investigators centers achieving pharmacokinetic examination)
* Well-informed written consent, signed by the patient
Exclusion Criteria
* Patient with clinically detectable cerebral metastasis
* Pregnant or nursing women
* Patient under guardianship or trusteeship
* Patient whose venous status don't permit a peripheral intravenous administration route's placing (for Investigators centers achieving pharmacokinetic examination)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Claudius Regaud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Institut Claudius Regaud
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurence GLADIEFF, Doctor
Role: PRINCIPAL_INVESTIGATOR
Institut Claudius Regaud
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Paul Papin
Angers, , France
Institut Bergonié
Bordeaux, , France
Clinique Pasteur
Évreux, , France
CHU A. Michallon
Grenoble, , France
Centre Oscar Lambert
Lille, , France
CHU de la Timone
Marseille, , France
Centre Val d'Aurelle
Montpellier, , France
Centre Antoine Lacassagne
Nice, , France
CHU de Nîmes
Nîmes, , France
Hopital Européen Georges Pompidou
Paris, , France
Clinique Mathilde
Rouen, , France
Centre René Gauducheau
Saint Herblain (Nantes), , France
CHU de Toulouse Rangueil
Toulouse, , France
Institut Claudius Regaud
Toulouse, , France
CHRU Bretonneau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04 GENE 05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.